The OS for men’s health — for a practice that is more than a testosterone clinic

Q: Guidelines act at 54% on therapy and I hold at my own line. Will it argue?

It shows your line. A doctor who holds at 52% writes that in the note, and the record carries that target beside the marker’s trend, so Clinical Intelligence can tell you where he stands against that line, with the source. The decision to hold stays yours.

Q: Will it read the PI-RADS off my MRI report?

You read it. The MRI and the coronary CT go on file beside his labs, dated and by kind, and iksa takes the PI-RADS and the density from what you wrote down.

Q: Do we see free testosterone, SHBG and estradiol, or just the total?

Each on its own line. Total and free testosterone, SHBG and estradiol each keep their own line, with the date and the source report behind them.

Q: What happens with a man I decide not to treat?

He hears your reasons. Your reasons sit in your note, whether it’s a PSA over 4, or over 3 in a man at higher risk (a Black man, one with a father or brother with prostate cancer, or a BRCA2 carrier), a hematocrit already high, untreated severe apnea or an MI in the past six months. A plan for children rules out testosterone but not treatment, since the AUA lets you keep his fertility with hCG, a SERM or an aromatase inhibitor. Patient AI explains what you wrote, and drafts come from your approved answers.

Q: What does he hear when he asks Patient AI for a higher dose?

That it’s your call. Patient AI explains his results from his record and what you wrote, and tells him a change in therapy is your call and, if he says yes, flags the question to your nurse.

Q: I already run men’s health clinic software. Do I have to replace it?

Keep it. iksa reads your charts from your EHR, by connection or by upload, while your booking system goes on running the calendar. It holds years of PSA, hematocrit and imaging reports around one man’s therapy, and the decisions made on them.

Q: I went looking for an OS for men’s health and mostly found TRT clinic software. Is this one of those?

Not one of those. We call it the harness for n-of-1 medicine, because the trials tell you about men on average and your dose has to answer to one man’s prostate, heart and hematocrit.

iksa is the harness for n‑of‑1 medicine. Your program keeps a trial’s watch on every man on testosterone, with PSA and hematocrit on his nurse’s list before anyone weighs the next dose.

Request a walkthrough

Patient N, 54, Testosterone therapy, Year 2. Prostate MRI, 3T, Month 15, after a confirmed rise in his PSA. PSA density 0.08 ng/mL/cm³, reference Under 0.15. PI-RADS 2: Clinically significant cancer unlikely. Prostate volume: 38 cm³; Transition zone: Mostly encapsulated nodule; Peripheral zone: No focal lesion; Before therapy: Coronary calcium score 0. Next: No biopsy, same testosterone dose; PSA every six months; Prostate MRI again if density reaches 0.10. — Illustrative

Four readings decide a testosterone dose, and only one of them is testosterone

Whether a man starts is your decision on the numbers, and the ones you treat you run as a trial of one, where the next PSA or hematocrit can hold the dose, lower it or send him to an MRI. TRAVERSE found testosterone noninferior to placebo for major cardiac events in men with or at high risk of heart disease, with more atrial fibrillation, pulmonary embolism and acute kidney injury. Since then FDA has asked to lift the label’s limit on age-related low testosterone.

Testosterone and SHBGTwo fasting morning draws confirm the deficiency and LH and FSH say where it comes from, then total and free testosterone with SHBG, drawn at the same point between doses, tell you whether the dose moves. Whether it’s working is in his own account of erections, drive and mood, and when his level comes up and they don’t, the AUA has you talk about stopping at three to six months. Three to six months after starting, as the Endocrine Society sets it, then at his yearly review.
Hematocrit and blood pressureThe AUA holds off starting above a hematocrit of 50% and acts at 54% on therapy, where the Endocrine Society stops it, and one large cohort saw more heart and clot events from 52%. You hold at a line you chose, look for sleep apnea and restart lower. The class label now warns of rising blood pressure and has dropped its boxed heart-risk language. Before the first dose, three to six months after starting, then yearly and at every dose review.
PSA and prostate MRIA rise has to repeat before it counts, and the guideline’s lines are over 1.4 ng/mL in the first year or a confirmed PSA over 4. MRI then comes before any biopsy, and a PI-RADS 2 is read with its PSA density, because above a density of 0.10 that man can still go to biopsy. PSA before the first dose, three to twelve months after starting, then as his screening calls for. MRI when a rise repeats.
Coronary CTA calcium score before the first dose is your rule, from the cardiology guideline that sorts a man’s risk by it (ACC/AHA 2019), since no testosterone guideline asks for one. A CT angiogram shows the non-calcified plaque that grew more on testosterone in the Testosterone Trials’ older men. The testosterone guidelines’ own heart line is no first dose within three to six months of a cardiac event (AUA) or six months of an MI or stroke (Endocrine Society). Once, before the first dose. An angiogram when his risk calls for it.

An MRI and a PSA density are why his rising PSA led to no biopsy and the same dose

Had 3.1 been his PSA at entry it would have kept him out of TRAVERSE, so his doctor made this decision on his own numbers.

Patient N, 54's coronary calcium score was 0 before therapy (risk low, no angiogram, with his blood pressure read at each visit), and on therapy his PSA of 3.1 ng/mL rose and a repeat draw confirmed it, the MRI read PI-RADS 2, and his doctor decided on no biopsy and the same dose, with his hematocrit at 49%.

Let’s look at what your program does with a man on testosterone who is drifting toward a PSA you’d have to act on, while it’s still a drift.

Request a walkthroughRequest a walkthrough for men’s health

A testosterone trial pays monitors, adjudicators and statisticians to watch a man like him, and your program keeps that watch on him

No clinic can staff a coordinating center and a safety board for one man on therapy, so that work sits with your program. DEA’s telemedicine flexibilities for testosterone run through December 31, 2026, with a final rule under review, so which men started without an in-person evaluation belongs in your record.

Loss to follow-up
The man who has gone quiet since his last dose change is the one that worries you, and only one nurse’s list would show it, beside whose PSA is due and whose MRI comes back if his PSA keeps climbing.
Central lab
One lab reports testosterone in ng/dL and the next in nmol/L, so a man’s history has to be converted in your head.
Safety reporting
The atrial fibrillation and clots TRAVERSE found more of would show up as palpitations, a swollen calf or sudden breathlessness mentioned on a Sunday. A large trial sends each suspected event to an adjudication committee, and a clinic has the person who knows him.
Biostatistics
PSA climbs on testosterone in the first year anyway and swings from draw to draw, so telling that from a rise that matters means lining up years of his values by hand.

No biopsy and the same dose is one decision, which he can have explained, his nurse follows and his doctor’s note holds

The next time his hematocrit comes back near his doctor’s line, the harness already knows his PSA history and what was written about the MRI, and the decision to hold is still his doctor’s.

His doctor can go into a dose review with every PSA since the first dose, each tied to its lab report
Clinical Intelligence lists each PSA in the lab’s own words and says when a draw isn’t on file. A testosterone in ng/dL or nmol/L reaches his doctor only after it’s checked against its source page and passes unit, range, flag and identity checks, and one that misses is held back.
Clinical Intelligence: clinical AI and lab tracking
His nurse has his hematocrit and PSA on the panel’s list, by marker and status, with his series one click away
Your nurse reviews each flag and resolves it. A man asking whether testosterone is right for him gets an Agentic CRM draft built only from what you’ve already said, naming where those answers stop, and your team approves or edits it before it goes out.
Agentic CRM: scheduling and follow-up
Why a rising PSA meant no biopsy is in his doctor’s note, and Patient AI can take him through it
Patient AI answers from his own record and explains what his doctor wrote. A message about palpitations or a swollen calf gets safety questions first, and if that calls for a person it goes to his nurse or doctor with what he’s told it.
Patient AI: the treatment companion

Men stay on testosterone for years, longer than the trials follow them, so your panel holds what the evidence is missing

A urologist reading his chart years from now can see what was read and what was written at Month 15. De-identified and with each man’s consent, the same history across your panel would give a research group somewhere to start a first study, on how PSA and hematocrit behave over years of therapy. How a research group would start from your panel →

What you’d ask when the prostate, the heart and the hematocrit all come before the dose

Guidelines act at 54% on therapy and I hold at my own line. Will it argue?

It shows your line.A doctor who holds at 52% writes that in the note, and the record carries that target beside the marker’s trend, so Clinical Intelligence can tell you where he stands against that line, with the source. The decision to hold stays yours.

Will it read the PI-RADS off my MRI report?

You read it.The MRI and the coronary CT go on file beside his labs, dated and by kind, and iksa takes the PI-RADS and the density from what you wrote down.

Do we see free testosterone, SHBG and estradiol, or just the total?

Each on its own line.Total and free testosterone, SHBG and estradiol each keep their own line, with the date and the source report behind them.

What happens with a man I decide not to treat?

He hears your reasons.Your reasons sit in your note, whether it’s a PSA over 4, or over 3 in a man at higher risk (a Black man, one with a father or brother with prostate cancer, or a BRCA2 carrier), a hematocrit already high, untreated severe apnea or an MI in the past six months. A plan for children rules out testosterone but not treatment, since the AUA lets you keep his fertility with hCG, a SERM or an aromatase inhibitor. Patient AI explains what you wrote, and drafts come from your approved answers.

What does he hear when he asks Patient AI for a higher dose?

That it’s your call.Patient AI explains his results from his record and what you wrote, and tells him a change in therapy is your call and, if he says yes, flags the question to your nurse.

I already run men’s health clinic software. Do I have to replace it?

Keep it.iksa reads your charts from your EHR, by connection or by upload, while your booking system goes on running the calendar. It holds years of PSA, hematocrit and imaging reports around one man’s therapy, and the decisions made on them.

I went looking for an OS for men’s health and mostly found TRT clinic software. Is this one of those?

Not one of those.We call it the harness for n‑of‑1 medicine, because the trials tell you about men on average and your dose has to answer to one man’s prostate, heart and hematocrit.

What is n‑of‑1 medicine?All practices iksa beside your EHR Protocol management software What iksa adds

Tell us how your men’s health program runs, down to the hematocrit you hold at and the PSA you act on

Bring a protocol you run. We’ll walk one patient through it.